檢索結果 - Preetesh Jain

Refine Results
  1. 1
    <scp>C</scp>hronic lymphocytic leukemia (CLL)—<scp>T</scp>hen and now

    <scp>C</scp>hronic lymphocytic leukemia (CLL)—<scp>T</scp>hen and now 由 R. Kanti, Preetesh Jain

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

    Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management 由 Preetesh Jain, Michael Wang

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Recent advances in de novo CD5<sup>+</sup> diffuse large B cell lymphoma

    Recent advances in de novo CD5<sup>+</sup> diffuse large B cell lymphoma 由 Preetesh Jain, Luis Fayad, Andreas Rosenwald, Ken H. Young, Susan O’Brien

    出版 2013
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis

    Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis 由 Holly A. Hill, Xinyue Qi, Preetesh Jain, Krystle Nomie, Yucai Wang, Shouhao Zhou, Michael Wang

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations

    Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations 由 Yuxuan Che, Yang Liu, Yixin Yao, Holly A. Hill, Yijing Li, Qingsong Cai, Fangfang Yan, Preetesh Jain, Wei Wang, Lixin Rui, Michael Wang

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

    Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia 由 Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop M. Kantarjian, Susan O’Brien, Jan A. Burger

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

    Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib 由 Preetesh Jain, Philip A. Thompson, Michael J. Keating, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Hagop M. Kantarjian, Jan A. Burger, Susan O’Brien, William G. Wierda

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia

    Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia 由 Xiao‐Jie Yan, Igor Dozmorov, Wentian Li, Sophia Yancopoulos, Cristina Sison, Michael Centola, Preetesh Jain, Steven L. Allen, Jonathan E. Kolitz, R. Kanti, Nicholas Chiorazzi, Barbara Sherry

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

    Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib 由 Preetesh Jain, Michael J. Keating, William G. Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle F. James, Hagop M. Kantarjian, Jan A. Burger, Susan O’Brien

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells

    STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells 由 Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating, Zeev Estrov

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

    Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials 由 Koji Sasaki, Sara S. Strom, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Preetesh Jain, Sherry Pierce, Hagop M. Kantarjian, Jorge E. Cortés

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

    Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy 由 Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Hun Ju Lee, Lucy Navsaria, Raphaël Steiner, Sairah Ahmed, Omar Moghrabi, Onyeka Oriabure, Wendy Chen, Maria Badillo, Christopher R. Flowers, Michael Wang

    出版 2020
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  13. 13
    Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

    Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study 由 Preetesh Jain, Hagop M. Kantarjian, Elias Jabbour, Graciela Nogueras González, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Evguenia Gachimova, Alessandra Ferrajoli, Steven M. Kornblau, Farhad Ravandi, Susan O’Brien, Jorge E. Cortés

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

    Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities 由 Preetesh Jain, Hagop M. Kantarjian, Aziz Nazha, Susan O’Brien, Elias Jabbour, Carlos G. Romo, Sherry Pierce, Marylou Cárdenas-Turanzas, Srđan Verstovšek, Gautam Borthakur, Farhad Ravandi, Alfonso Quintás‐Cardama, Jorge E. Cortés

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Four‐year follow‐up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>)

    Four‐year follow‐up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>... 由 Preetesh Jain, Jorge Romaguera, Samer A. Srour, Hun Ju Lee, Frederick Hagemeister, Jason R. Westin, Luis Fayad, Felipe Samaniego, Maria Badillo, Liang Zhang, L. Nastoupil, Rashmi Kanagal‐Shamanna, Nathan Fowler, Michael Wang

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

    Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes 由 Ohad Benjamini, Preetesh Jain, Long Trinh, Wei Qiao, Sara S. Strom, Susan Lerner, Xuemei Wang, Jan A. Burger, Alessandra Ferrajoli, Hagop M. Kantarjian, Susan O’Brien, William G. Wierda, Zeev Estrov, Michael J. Keating

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials

    Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid le... 由 Preetesh Jain, Hagop M. Kantarjian, Mona Lisa Alattar, Elias Jabbour, Koji Sasaki, Graciela Nogueras González, Sara Dellasala, Sherry Pierce, Srđan Verstovšek, William G. Wierda, Gautam Borthakur, Farhad Ravandi, Susan O’Brien, Jorge E. Cortés

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

    Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells 由 Uri Rozovski, Srđana Grgurević, Carlos Bueso-Ramos, David Harris, Ping Li, Zhiming Liu, Ji Yuan Wu, Preetesh Jain, William G. Wierda, Jan A. Burger, Susan O’Brien, Nitin Jain, Alessandra Ferrajoli, Michael J. Keating, Zeev Estrov

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

    Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial 由 Dai Chihara, Hagop M. Kantarjian, Susan O’Brien, Jeffrey L. Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Rebecca Poku, Preetesh Jain, Philip A. Thompson, Mark Brandt, Rajyalakshmi Luthra, Jan A. Burger, Michael J. Keating, Farhad Ravandi

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

    Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance 由 Preetesh Jain, Mohammad Javdan, Franziska Feger, Percy Chiu, C. Sison, Rajendra N. Damle, Tanzim Bhuiya, Filiz Şen, Lynne V. Abruzzo, Jan A. Burger, Andreas Rosenwald, Steven L. Allen, Jonathan E. Kolitz, Michael R. Kanost, Nicholas Chiorazzi, Barbara Sherry

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: